A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

Overview

This is a study designed to evaluate the efficacy and safety of lurasidone in acutely psychotic patients with chronic schizophrenia and to confirm the non-inferiority of lurasidone relative to quetiapine XR.

Full Title of Study: “A Phase 3 Randomized, Double-Blind, Active-controlled Study to Evaluate the Efficacy and Safety of Lurasidone in Acutely Psychotic Patients With Schizophrenia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: October 26, 2022

Interventions

  • Drug: Lurasidone HCL 160 mg
    • Lurasidone HCL 2 80mg tablets, QD
  • Drug: Quetiapine XR 600 mg
    • Quetiapine XR 2 300 mg tablets, QD

Arms, Groups and Cohorts

  • Experimental: Lurasidone HCL 160 mg
    • Lurasidone HCL 160 mg/day
  • Active Comparator: Quetiapine XR 600 mg
    • Quetiapine XR 600 mg/day

Clinical Trial Outcome Measures

Primary Measures

  • Mean change in Total PANSS Score From Baseline at Week 6
    • Time Frame: Week 6
    • The PANSS (Positive and Negative Syndrome Scale) is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.

Secondary Measures

  • Mean change in CGI-S score From Baseline at Week 6
    • Time Frame: Week 6
    • Clinical Global Impression of Severity is a clinician-rated assessment of the subject’s current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 (‘normal’, not ill) to 7 (extremely ill).

Participating in This Clinical Trial

Inclusion Criteria

1. Provide written informed consent and aged between 19 and 75 years of age. 2. Meets DSM-5 criteria for a primary diagnosis of schizophrenia. 3. CGI-S ≥ 4 at screening and baseline. 4. Subject is not pregnant (must have a negative serum pregnancy test at screening) or nursing (must not be lactating) and is not planning pregnancy within the projected duration of the study. 5. Subject is able and agrees to remain off prior antipsychotic medication for the duration of the study. 6. Subject is in good physical health on the basis of medical history, physical examination, and laboratory screening. Exclusion Criteria:

1. The subject has evidence of any chronic organic disease of the CNS (other than schizophrenia) 2. Subject has participated in a prior trial of lurasidone. 3. Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months. 4. In the opinion of the investigator, subject is unable to cooperate with any study procedures, unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study. 5. Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bukwang Pharmaceutical
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jung Hee Yeon, Principal Investigator, SMG-SNU Boramae Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.